Bharat Biotech has officially released the final analysis of Phase-3 trial of Covaxin. According to this, the vaccine has been found to be 77.8 percent effective against the virus. Along with this, it is 65.2 percent effective against the delta variant of the corona virus.
At the same time, it has been found to be 93.4 percent effective against severe infection of corona virus. Covaxin has been found to be 78 percent effective in cases of mild and severe Covid-19. It is 63% effective in asymptomatic cases. The company said in its results that 25,800 volunteers aged 18 to 98 years were included in the trial. The trial was conducted at 25 places across the country. After giving both doses to the volunteers involved in the trial, their health was monitored for about two weeks.
It is worth noting that the vaccine which is currently allowed in India to be used in the war against Corona in the country includes indigenously developed covaxin. Bharat Biotech had handed over the trial data of Phase III of the Made in India Covid-19 vaccine to DCGI some time back. Earlier, DCGI had given permission to Covaxin for emergency use in India in the month of January on the basis of Phase I and Phase II trial data.
At the same time, more than 34 crore vaccine doses have been given in India. According to the Union Health Ministry, 34,00,76,232 vaccine doses have been given till Friday morning, in which 27,94,54,091 people have been given the first dose while 6,06,22,141 both doses have been given. 8,92,46,934 people in the age group of 45 to 59 years have been given the first and 1,68,55,676 people have been given the second dose of corona vaccine. Whereas 6,83,55,887 people above 60 years of age have been given the first and 2,46,70,576 second doses.